Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate the rate of adherence to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) and to determine the factors relating to adherence among these patients. Method: The research was a cross sectional descriptive study in all CML patients receiving TKI in Hematology Clinic, Songklanagarind Hospital during December 2015 to March 2016. The study assessed adherence to medication therapy by three methods including pill count, calculation of medication possession ratio, and the Medication Taking Behavior questionnaire in Thai patients (MTB-Thai). Results: Seventy-nine patients were enrolled in the study. The proportion of subjects receiving medication treatment with imatinib and nilotinib were 54.4% and 45.6%, respectively. Seventeen patients (21.5%) were classified in the high adherence group. Gender, age, body mass index, religion, educational level, occupation, health insurance coverage, marital status, care takers of medication uses and number of comorbid conditions did not affect the patient’s adherence. Conclusion: Only 21.5% of CML patients had a high level of adherence to TKIs treatment. However, 78.5% of patients were classified as having inadequate adherence potentially leading to treatment failure. The assessment of TKIs adherence among CML patients should employed more than one approaches to ensure the accuracy.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, et al. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challeng es and opportunities in the targeted therapy era. Leuk Res 2010; 34: 1459-71.
3. Drug Bureau, Food and Drug Administration. Handbook on rational use of E(2) drugs in Thai national list of essential medicines. Bangkok: Agricultural Cooperative Federation of Thailand; 2010
4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
5. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044-54.
6. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imati nib in newly diagnosed chronic-phase chronic mye- loid leukemia: 2-year follow-up from a randomizeed phase 3 trial (DASISION). Blood 2012; 119: 1123-9.
7. Jutha S, Boonworaset U, Puawilai T, Numbenjapon T, Naraworawong W, Lekhakul A, et al. Chronic myeloid leukemia for Thailand [online]. 2011 [cited Aug 25, 2015]. Available from: www.tsh.or.th/file_up load/files/Chronic%20Myeloid%20Leukemia.doc.
8. Noens L, van Lierde MA, De Bock R, Verhoef G, Zac hée P, Berneman Z, et al. Prevalence, determinants , and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401-11.
9. Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012; 87: 687-91.
10. Almeida MH, Fogliatto L, Couto D. Almeida MH, Fogliatto L, Couto D. Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Rev Bras Hematol Hemoter 2014; 36: 54-9.
11. Almeida MH, Pagnano KB, Vigorito AC, Lorand-Metze I, de Souza CA. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. Acta Haematol 2013; 130: 16-22.
12. Kekäle M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M. Chronic myeloid leukemia patients' adherence to per oral tyrosine kinase inhibitors compared with adherence as estimated by their phy sicians. Patient Prefer Adherence 2014; 8: 1619-27.
13. Marin D, Bazeos A, Mahon FX, Eliasson L, Miloj kovic D, Bua M, et al. Adherence is the critical factor for achieving molecular response in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-8.
14. Hosoya K, Mochinaga S, Emoto A, Yokoo H, Tokushima H, Egoshi M, et al. Sueoka-Aragane N, Kimura S. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. Int J Clin Oncol 2015;20:1203-10.
15. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074-90.
16. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence 2013; 7: 509-16.
17. Sakthong P, Sonsa-Ardjit N, Sukarnjanaset P, Mun pan W, Suksanga P. Development and psychometric testing of the medication taking behavior tool in Thai patients. Int J Clin Pharm 2016; 38: 438-45.
18. Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 2014; 99: 437-47.
19. Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract 2016; 22:741-48.
20. Moulin SM, Eutrópio FJ, Souza JO, Busato FO, Olivieri DN, Tadokoro CE. The role of clinical pharma cists in treatment adherence: fast impact in suppres sion of chronic myeloid leukemia development and symptoms. Support Care Cancer 2017; 25: 951-55.
21. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, Mitchell WD, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989; 46: 169-76.
22. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61-9.
23. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated health care costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25: 481-96.
24. Lim YM, Eng WL, Chan HK. Understanding and challenges in taking tyrosine kinase inhibitors among Malaysian chronic myeloid leukemia patients: A qualitative study. Asian Pac J Cancer Prev 2017; ;18: 1925-30.
